Flavanone metabolism in healthy and tumor-bearing rats

Biomedicine and Pharmacotherapy

Volumn 60, Issue 9, 2006, Pages 529-535

  Silberberg, M ^a   Gil Izquierdo, A ^a   Combaret, L ^a   Remesy, C ^a   Scalbert, A ^a   Morand, C ^a  

^a CEMAGREF   (France)

Author keywords

Bioavailability; Cancer; Flavanones; Metabolism

Indexed keywords

FLAVANONE; FLAVANONE DERIVATIVE; NARINGENIN;

ANIMAL; ARTICLE; EXPERIMENTAL NEOPLASM; MALE; METABOLISM; RAT; WISTAR RAT;

ANIMALS; FLAVANONES; MALE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, WISTAR;

EID: 33750290817     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.07.083     Document Type: Article

References (36)

1. Scalbert A., Manach C., Morand C., Rémésy C., and Jiménez L. Dietary polyphenols and the prevention of diseases. Crit. Rev. Food Sci. Nutr. 45 4 (2005) 287-306
2. Manach C., Scalbert A., Morand C., Remesy C., and Jimenez L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79 5 (2004) 727-747
3. Tomas Barberan F.A., and Clifford M.N. Flavanones, chalcones, and dihidroxychalcones-nature, occurence and dietary burden. J. Sci. Food Agric. 80 (2000) 1073-1080
4. Rousseff R.L., Martin S.F., and Youtsey C.O. Quantitative survey of narirutin, naringin, heperidin, and neohesperidin in Citrus. J. Agric. Food Chem. 35 (1987) 1027-1030
5. Wilcox L.J., Borradaile N.M., de Dreu L.E., and Huff M.W. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J. Lipid Res. 42 5 (2001) 725-734
6. Borradaile N.M., de Dreu L.E., Barrett P.H., Behrsin C.D., and Huff M.W. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 42 5 (2003) 1283-1291
7. Lee S.H., Park Y.B., Bae K.H., Bok S.H., Kwon Y.K., Lee E.S., et al. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme A:cholesterol acyltransferase in rats. Ann. Nutr. Metab. 43 3 (1999) 173-180
8. Kanno S., Tomizawa A., Hiura T., Osanai Y., Shouji A., Ujibe M., et al. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol. Pharm. Bull. 28 3 (2005) 527-530
9. So F.V., Guthrie N., Chambers A.F., Moussa M., and Carroll K.K. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr. Cancer 26 2 (1996) 167-181
10. Crespy V., Morand C., Besson C., Cotelle N., Vezin H., Demigne C., et al. The splanchnic metabolism of flavonoids highly differed according to the nature of the compound. Am. J. Physiol. Gastrointest. Liver Physiol. 284 6 (2003) G980-G988
11. Silberberg M., Morand C., Mathevon T., Besson C., Manach C., Scalbert, et al. The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur. J. Nutr. (2005)
12. Sesink A.L., Arts I.C., de Boer V.C., Breedveld P., Schellens J.H., Hollman P.C., et al. Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol. Pharmacol. 67 6 (2005) 1999-2006
13. Dietrich C.G., Geier A., and Oude Elferink R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 12 (2003) 1788-1795
14. Basinska A., and Florianczyk B. Beta-glucuronidase in physiology and disease. Ann. Univ. Mariae Curie Sklodowska [Med.] 58 2 (2003) 386-389
15. de Graaf M., Boven E., Scheeren H.W., Haisma H.J., and Pinedo H.M. Beta-glucuronidase-mediated drug release. Curr. Pharm. Des. 8 15 (2002) 1391-1403
16. Yuan L., Wagatsuma C., Sun B., Kim J.H., and Surh Y.J. The role of beta-glucuronidase in induction of apoptosis by genistein combined polysaccharide (GCP) in xenogeneic mice bearing human mammary cancer cells. Ann. N. Y. Acad. Sci. 1010 (2003) 347-349
17. Leslie E.M., Deeley R.G., and Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204 3 (2005) 216-237
18. Plasschaert S.L., Van Der Kolk D.M., De Bont E.S., Vellenga E., Kamps W.A., and De Vries E.G. Breast cancer resistance protein (BCRP) in acute leukemia. Leuk. Lymphoma 45 4 (2004) 649-654
19. Oudart H., Heitz A., Bnouham M., Malan A., and Le Maho Y. Body protein and lipid deficit in tumour-bearing rats in relation to age. Br. J. Cancer 68 5 (1993) 885-889
20. Nikolic D., and van Breemen R.B. New metabolic pathways for flavanones catalyzed by rat liver microsomes. Drug Metab. Dispos. 32 4 (2004) 387-397
21. Matsumoto M., Matsukawa N., Mineo H., Chiji H., and Hara H. A soluble flavonoid-glycoside, alphaG-rutin, is absorbed as glycosides in the isolated gastric and intestinal mucosa. Biosci. Biotechnol. Biochem. 68 9 (2004) 1929-1934
22. Morand C., Manach C., Crespy V., and Rémésy C. Quercetin 3-O-beta-glucoside is better absorbed than other quercetin forms and is not present in rat plasma. Free Rad. Res. 33 (2000) 667-676
23. Felgines C., Texier O., Morand C., Manach C., Scalbert A., Regerat F., et al. Bioavailability of the flavanone naringenin and its glycosides in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 279 6 (2000) G1148-G1154
24. Day A.J., Mellon F., Barron D., Sarrazin G., Morgan M.R., and Williamson G. Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic. Res. 35 6 (2001) 941-952
25. Ameer B., Weintraub R.A., Johnson J.V., Yost R.A., and Rouseff R.L. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Therap. 60 1 (1996) 34-40
26. Mohsen M.A., Marks J., Kuhnle G., Rice-Evans C., Moore K., Gibson G., et al. The differential tissue distribution of the citrus flavanone naringenin following gastric instillation. Free Radic. Res. 38 12 (2004) 1329-1340
27. Meng X., Lee M.J., Li C., Sheng S., Zhu N., Sang S., et al. Formation and identification of 4′-o-methyl-(-)-epigallocatechin in humans. Drug Metab. Dispos. 29 6 (2001) 789-793
28. Hosny M., Dhar K., and Rosazza J.P. Hydroxylations and methylations of quercetin, fisetin, and catechin by Streptomyces griseus. J. Nat. Prod. 64 4 (2001) 462-465
29. Dhar K., and Rosazza J.P. Purification and characterization of Streptomyces griseus catechol O-methyltransferase. Appl. Environ. Microbiol. 66 11 (2000) 4877-4882
30. De Eds F., Booth A.N., and Jones T.F. Methylation and dehydroxylation of phenolic compounds by rats and rabbit. J. Biol. Chem. 225 6 (1957) 615-621
31. Chen L.S., Lee M.J., Li H., and Yang C.S. Absorption, distribution, and elimination of tea polyphenols in rats. Drug Metab. Dispos. 25 9 (1997) 1045-1050
32. Chow H.H., Cai Y., and Alberts D. Phase I pharmacokinetics study of tea polyphenols following single dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol. Biomarkers Prev. 10 (2001) 53-58
33. O'Leary K.A., Day A.J., Needs P.W., Mellon F.A., O'Brien N.M., and Williamson G. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem. Pharmacol. 65 3 (2003) 479-491
34. Vaidyanathan J.B., and Walle T. Cellular uptake and efflux of the tea flavonoid (-)epicatechin-3-gallate in the human intestinal cell line Caco-2. J. Pharmacol. Exp. Ther. 307 2 (2003) 745-752
35. Chen J., Lin H., and Hu M. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother. Pharmacol. 55 2 (2005) 159-169
36. Luqmani Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 14 Suppl 1 (2005) 35-48